← All QL Wire
Share:
$PFE QuantLogix Newsdesk · June 4, 2026 at 3:32 PM UTC

PFE, BMY Yields Compared in Motley Fool Dividend Piece

What happened

The Motley Fool published a side-by-side analysis on June 4 comparing Pfizer (PFE) and Bristol Myers Squibb (BMY) as high-yield dividend options within large-cap pharma. Both companies carry dividend yields elevated relative to the broader S&P 500. Pfizer shares closed at $25.72 on the session, reflecting a stock price that has remained under multi-year pressure and consequently pushed its yield into high-yield territory. The piece carried a neutral sentiment score, reflecting no clear editorial preference for either name.

The QL Read

QuantLogix composite for PFE sits at 44/100 (Neutral), suggesting no decisive factor tilt currently behind the name. The +1.60% session move is worth noting in context: any sustained move higher from the $25.72 level would mechanically reduce the forward yield that anchors the comparison.

Source: The Motley Fool — "Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?" — 2026-06-04T06:30:00Z
Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.